BioMarin Pharmaceutical Inc.
NASDAQ:BMRNBiotechnology
-$0.10 today
- Market cap
- $11.90B
- Beta
- 0.24
- P/E (TTM)
- 39.4
- EPS (TTM)
- $1.40
Volume 3.07M
Average 2.04M
BMRN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
BioMarin Pharmaceutical Inc.NASDAQ: BMRN
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns negative
Q3 FY2026 accounts receivables was -$60.39B, compared with $48.75M a year earlier. Trailing-twelve-month accounts receivables was -$60.56B. Over 3 fiscal years it compounded at +40.6% a year.
Context
- Accounts receivables amounted to 7.1% of revenue in FY2025, up 5.1 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$60.39B or moves back toward the trailing-twelve-month quarterly average of -$15.14B.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (228.05M) USD
- Year-over-year change
- -293.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (228.05M) | -293.8% |
| FY2024 | 2024-12-31 | (57.91M) | +69.6% |
| FY2023 | 2023-12-31 | (190.44M) | -132.1% |
| FY2022 | 2022-12-31 | (82.03M) | -225.1% |
| FY2021 | 2021-12-31 | 65.57M | — |
Accounts Receivables vs competitors
How BMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +173755.7% is the highest of 11, against a peer median of +18.6%.
- Accounts receivables amounts to 5.9% of revenue for BMRN, versus a peer median of 5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.56B USD | +173755.7% | +40.6% | 5.9% | |
| LTM Jun 2026 | $357.64M USD | +48.4% | +99.1% | 7.4% | |
| LTM Jun 2026 | $259.7M USD | +52.0% | -1.1% | 2.1% | |
| LTM Jun 2026 | $177.62M USD | +133.1% | — | 24.9% | |
| LTM Jun 2026 | $162.88M USD | +1189.3% | +139.6% | 14.3% | |
| LTM Sep 2026 | €88.44M EUR | -11.3% | — | 7.3% | |
| LTM Sep 2026 | $63.73M USD | -14.2% | -10.4% | 6.6% | |
| LTM Jun 2026 | $44.38M USD | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $22.06M USD | -1708.0% | +37.0% | 3.3% | |
| LTM Sep 2026 | $13.84M USD | -76.0% | +168.7% | 2.1% | |
| LTM Mar 2026 | $13.18M USD | +49.0% | — | 3.6% | |
| Peer median (excluding BMRN) | — | +18.6% | +37.0% | 5.5% | |
Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.08M) | 141.56M | 167.65M | 426.86M | 348.9M |
| Depreciation & Amortization | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| Deferred Income Tax | (15.61M) | (52.09M) | (44.98M) | 56.1M | 48.74M |
| Stock-Based Compensation | 197.26M | 196.31M | 207.1M | 201.57M | 181.41M |
| Change in Working Capital | 66.03M | (96.38M) | (336.54M) | (216.4M) | (108.68M) |
| Accounts Receivables | 65.57M | (82.03M) | (190.44M) | (57.91M) | (228.05M) |
| Inventory | (35.06M) | (68.26M) | (157.06M) | (63.53M) | 119.21M |
| Accounts Payables | 15.69M | 59.02M | 68.85M | (32.24M) | 66.14M |
| Other Working Capital | 19.83M | (5.1M) | (57.9M) | (62.72M) | (65.97M) |
| Other Non-Cash Items | 12.89M | (115.47M) | 61.65M | 8.29M | 278.07M |
| Operating Cash Flow | 304.54M | 175.9M | 159.26M | 572.84M | 827.99M |
| Capital Expenditures | (119.23M) | (120.96M) | (107.61M) | (97.42M) | (103.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (285.19M) |
| Purchases of Investments | (937.14M) | (611.81M) | (868.5M) | (410.25M) | (355.88M) |
| Sales of Investments | 691.05M | 620M | 864.86M | 633.02M | 337.8M |
| Other Investing Activities | (24.64M) | 103.33M | (10.92M) | (853K) | (7.94M) |
| Investing Cash Flow | (366.31M) | (20.03M) | (111.24M) | 136.49M | (414.24M) |
| Debt Repayment | (3.04M) | (2.61M) | (2.29M) | (494.99M) | 0 |
| Common Stock Issued | 0 | 69.33M | 69.35M | 0 | 14.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.99M | (85.38M) | (85.79M) | (31.46M) | (56.85M) |
| Financing Cash Flow | (48K) | (18.65M) | (18.73M) | (526.45M) | (42.39M) |
| Effect of Forex Changes | (57K) | 32K | 1.31M | 4.83M | (2.52M) |
| Net Change in Cash | (61.88M) | 137.26M | 30.6M | 187.72M | 368.84M |
| Free Cash Flow | 185.31M | 54.94M | 51.65M | 475.42M | 724.96M |
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
Intrinsic Alpha fair value
Locked
Current Price
$61.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.